ALKOVE-1 Trial

2026 ASCO ANNUAL MEETING ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC Jessica J. Lin1, Enriqueta Felip2, Byoung Chul Cho³, Benjamin Besse⁴, Geoffrey Liu⁵, Lorenza Landi6, Luis G. Paz-Ares⁷, Chiara Bennati⁸, Aurelie Swalduz9, Sanjay Popat¹⁰, Misako Nagasaka¹¹, Joshua E. Reuss¹², Christina S. Baik¹³, Julien Mazieres¹⁴, Melissa Johnson¹⁵, Adrianus Johannes de Langen¹⁶, Ji-Youn Han¹⁷, Malinda Itchins¹⁸, Viola W. Zhu¹⁹, Alexander Drilon20 Mass General Brigham Cancer Institute, Boston, MA, USA; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology Barcelona, Spain; Yonsei Cancer Center, Seoul, Republic of Korea; Paris Saclay University, Gustave Roussy, Villejuif, France: Princess Margaret Hospital, Toronto, Ontario, Canada "Istituto Nazionale Tumori Regina Elena, IRCCS, Rome, Italy: Hospital Universitario 12 de Octubre, Madrid, Spain; "Ospedale Santa Maria Delle Croci, Ravenna, Italy: Centre Leon Berard, Lyon, France; "Lung Unit, Royal Marsden Hospital, London, United Kingdom; "University of California Irvine Medical Center, Orange, CA, USA; Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA; Fred Hutchinson Cancer Center, Seattle, WA. USA; "Centre Hospitalier de Toulouse, Toulouse, France: Sarah Cannon Research Institute Oncology Partners, Nashville, TN. USA; Department of Thoracic Oncology, Antoni van Leeuwenhoek hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands; National Cancer Center, Goyang, Korea "Royal North Shore Hospital, Sydney, Australia; Nuvalent, Inc., Cambridge, MA, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO CLINICAL ONCOLOGY ANNUAL MEETING Presentation property author and Permasion required - KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by ± chemotherapy) + chemotherapy) ± chemotherapy) BICR N = 253 N 63 N = 190 Prior alectinib only + chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253)b 46% (29/63) 26% (50/190)ᵇ [95% CI] [26, 37] [33, 59] [20, 33] ≥2 prior ALK TKIs + chemotherapy: ORR = 28% (56/198) CR, % (n/N) 2% (6/253) c 5% (3/63) d 2% (3/190) d Median duration of follow-up of 11.3 months b Includes 2 single-timepoint PR pending confirmation for ongoing patients. Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. if Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naïve + chemotherapy 60 11171N: V11B0L 1 Prior ALK TKI (alectinib) 40 Best % change in target lesions 111717;L1196M 1 Prior ALK TKI (other) 20 11171N 11171N D1203N: 11171N G1202R G1202R L1196Q V1100L G1202R G1202R 111715 G1202R G1202R G1202R G1202R V1180L G1202R 2 Prior ALK TKIs 0 -20 3 Prior ALK TKIs -40 + Prior platinum 60 chemotherapy -80 Secondary ALK mutations listed above the column -100 PD PD PD PD PD SD NE so so SD SD so SD NE so so SD SD so so SD SD SD SD SD PR SD PR PR PR PR PR 5D PR PR PR PR PR PR PR PR SD PR PR PR PR PR WCR PR PR PR PR PR PR PR CR CR BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. 2026 ASCO #ASCO26 PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1 Preliminary Data: TKI-Naïve Patients with Advanced ALK+ NSCLC ALK TKI-naïve, BICR Response-evaluable CNS Response-evaluable ALK TKI-naïve, BICR N 44 N=9 ORR, % (n/N) 86% (38/44) IC-ORR, % (n/N) 78% (7/9) CR, % (n/N) 9% (4/44) b IC-CR, % (n/N) 44% (4/9) % DOR ≥ 12 months [95% CI] c 91% [70, 98] IC-DOR No CNS progression events among intracranial responders DOR range 1.7+ to 14.8+ months IC-DOR range 3.1+ to 7.0+ months a Includes 2 single-timepoint PR pending confirmation for ongoing patients. b Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Analyses of DOR based on if Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior Kaplan-Meier estimates confirmed IC-PR. 60 ALK TKI-naïve + chemotherapy 40 No prior chemotherapy Prior platinum chemotherapy Best % change in target lesions 20 0 -20 -40 -60 -80 -100 SD SD uPR uPR SD PR PR PR SD PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR SD PR PR PR PR PR CRCR CR CR BICR blinded independent central review, CI, confidence interval CNS central nervous system, CR, complete response, DOR duration of response, ORR, objective response rate, PD. progressive disease, PR. partial response, SD, stable disease, TKI fyrosine knase inhibitor 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Summary In these data from the ALKOVE-1 study of TKI-pretreated patients with advanced ALK+ NSCLC, neladalkib demonstrated a clinical profile consistent with its design goals: Meaningful clinical responses for TKI-pretreated patients (range 1-5 prior ALK TKI) across both lorlatinib-naive (ORR = 46%; median DOR not reached, DOR ≥12 months for 80%) and lorlatinib-experienced patients (ORR = 26%; median DOR of 17.6 months) Intracranial activity, including in patients who previously received lorlatinib, a population where no other TKI has shown activity (lorlatinib-naïve: IC-ORR = 63%; DOR ≥12 months for 92%; lorlatinib-experienced: IC-ORR = 21%; DOR ≥12 months for 55%) Activity in patients with ALK G1202R single or compound resistance mutations (lorlatinib-naïve: ORR = 83%, DOR ≥12 months for 77%; lorlatinib-experienced: ORR = 63%; DOR ≥12 months for 81%) Generally well-tolerated with low rates of dose reduction (17%) and treatment discontinuation (5%) due to TEAEs, consistent with its ALK-selective, TRK-sparing design Encouraging efficacy and safety data support investigation in the front-line setting in the ongoing phase 3 ALKAZAR trial (NCT06765109) 2026 ASCO PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY or #ASCO26 CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by : chemotherapy) : chemotherapy) : chemotherapy) BICR N 253 N 63 N 190 Prior alectinib only : chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253) 46% (29/63) 26% (50/190)b [95% CI] [26, 37] [20, 33] 22 prior ALK TKIs * chemotherapy: [33, 59] ORR - 28% (56/198) CR, % (n/N) 2% (6/253) C 5% (3/63) d 2% (3/190) d Median duration of follow-up of 11.3 months. b Includes 2 single-timepoint PR pending confirmation for ongoing patients. Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. a Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naive ± chemotherapy 60 1. V1180 1 Prior ALK TKI (alectinib) 40 INSURED 20 B171N G1202R H171N 01203N 81717 1 Prior ALK TKI (other) Best % change in target lesions G1202R V1180 012028 012028 111715 012028 G1202R WEBEVO 01242R VISABL NEBERD 2 Prior ALK TKIs 0 20 3 Prior ALK TKIs 40 Prior platinum 40 chemotherapy ao Secondary ALK mutations listed above the column 100 PO BICR, bilnded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. 2026 ASCO PRE SENTED BY Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY GE #ASCO26 CURICAL CHOLDER ANNUAL MEETING Presentation . property of the author and ASCO Permission required for - contact permissiona@asco.org CHOWLEDGE CONQUERS CANCER ASCO ASCO ASCO ASCO ASCO ASCO AS ASC ASCO ASCO ASCO SCO --- ALKOVE-1: Duration of Response TKI-Pretreated Any prior Lorlatinib- Lorlatinib- Kaplan-Meler Plot of DOR Advanced ALK+ ALK TKI naive experienced NSCLC (1-5 prior ALK TKI (1-3 prior ALK TKI (1-5 prior ALK TKI ALK TKI-Pretreated t chemotherapy) : chemotherapy) * chemotherapy) Kaplan-Meier Estimate 100 N=77 N 29 N 48 89% 80% DOR 2 6 months 76% 89% 68% 75 (95% CI] [64,84] [69,96] [52,80] 2 Response in Patients 60% 50 76% DOR > 12 months 64% 80% 54% 68% 64% (95% CI] 54% 53% [51,75] [58,91] [38,68] 47% 25 DOR ≥ 18 months 53% 60% 47% [95% CI] (34, 68] [19,85] [27,64] 0 0 6 12 18 24 Months Median DOR [95% CI] NR [14.5, NE] NR [14.5, NE] 17.6 (6.9, NE]* ALBak Any prior 77 48 20 a 2 Emerging median continues to mature. Lorlatinib- naive 29 21 7 2 1 Prior alectinib only 1 chemotherapy: median DOR - NR (95% CI: NE, NE). Lorlatinib 48 27 experienced 13 >2 prior ALK TKIs 1 chemotherapy: Emerging median DOR of 17.6 months (95% Cl: 7.1, NE) 6 1 continues to mature. CI, confidence interval; DOR, duration of response; NE, not estimable; NR. not reached; TKI, tyrosine kinase inhibitor. 2026 ASCO #ASCO26 PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO - CUPICAL SHOOLDS ANNUAL MEETING Presentation . property of the author and ASCO Permission required for - contact KNOWLEDGE CONQUERS CANCI ASCO ASCO ASCO ASCO ASCO CO ASC ASCO ASCO SCO ASCC AS ASCO AS

2026 ASCO ANNUAL MEETING a ASCO KT6 ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC in Gets maint us Sna Part istuiE Four ton' less time at laster 3 2026ASCO ANNUAL MEETING 2026 ASCO ANNUAL MEETING SEA ASCO SCO ASCO ASCO ASCO ASCO CO ASCO ASCO ASCO ASCO CB SU ASCO ASCO ASCO ASCO 50 ASCO ASCO ASCO ASCO ASCO ASCO CD SU ASCO ASCO ASCO ASCO ASCO ASCO ASCO --- ALKOVE-1: Pivotal TKI-Pretreated Patient Population Data cut-off: August 29, 2025 Total Enrolled: N = 781 Any ALK+ solid tumor, any dose Phase 1 + Phase 2 pooled Safety Population: N = 656 Advanced ALK+ NSCLC Received neladalkib at 150 mg QD Efficacy Population: ALK TKI-Pretreated a Preliminary Data with measurable disease by BICR TKI-Naïve b with measurable disease by BICR Treated by September 30, 2024 (> 6 months DOR follow up) Treated by August 29, 2025 n = 253 n = 44 a BICR, NTRK Includes blinded fusion 25 patients (n independent 1), with FGFR3 other central fusion oncogenic review; (n = 1). DOR, driver(s) ["One duration patient in addition of had response; both to ALK: KRAS NSCLC, MET G12C amplification non-small and BRAF (n cell mutations. : lung 9), KRAS cancer; G12C No QD, patients (n once = 4*), daily; with MET other TKI, mutation oncogenic tyrosine (n kinase # driver(s) 4), BRAF inhibitor. in mutation addition (1) to : ALK. 4°), RET fusion (n : 2), ER882 mutation in : 1), 2026 ASCO ANNUAL MEETING #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA Presentation is property of the author and ASCO Permission required for rever, contact permissions@asra.org ASCO - CHECK KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Any prior ALK TKI . Lorlatinib-naive Lorlatinib-experienced Advanced ALK+ (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs NSCLC : chemotherapy) 2 chemotherspy) : chemotherapy) Prior alectinib only : chemotherapy RECIST v1.1 by N 253 N 63 N = 190 BICR ORR a 48% (21/44, 5% CR) 31% (79/253) 46% (29/63) 26% (50/190)* ORR, % (n/N) 22 prior ALK TXIs : chemotherapy: (95% CI] (26, 37] (33, 59) (20, 33] ORR . 28% (56/198)* 2% (6/253) 5% (3/63) 2% (3/190)* CR, % (n/N) Median includes duration 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR 4 Includes 1 single-timepoint of follow-up of 11.3 months. includes 2 single-Imepoint PR pending confirmation for ongoing patients. CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naive * chemotherapy 1 Prior ALK TK) (sections) 8 VITAN I 1 Prior ALK TX) (other) 5 20 I 2 Prior ALK TKis Best % change in target lesions ) Prior ALK nos 0 Prior patrum 20 chemotheracy 40 Secondary ALK estations 40 listed above the - so BICR, binded -10 PO Independent central review, CL, confidence intervet CR, complete response; NE, not evaluable, ORR, objective response - PO. progressive PR, partal response so, - - ASCO TKL tyrosine unase inhibitor. HE SENTED - Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA USA - - - 2026 ASCO #ASCO26 ANNUAL MEETING JBL --- ALKOVE-1 Preliminary Data: TKI-Naïve Patients with Advanced ALK+ NSCLC ALK TKI-naive, BICR Response-evaluable ALK TKI-naive, BICR CNS Response-evaluable N 44 was ORR, % (n/N) 86% (38/44)* IC-ORR, % (n/N) 78% (779) CR, % (n/N) 9% (4/44) IC-CR, % (r/N) 44% (4/9)* % DOR 2 12 months (95% CI]< 91% [70, 98] No CNS progression events IC-DOR among Intracrantal responders DOR range 1.7+ to 14.8+ months IC-DOR range 3.1+ to 7.0+ months . includes 2 single-timepoint PR pending confirmation for ongoing patients Fincludes 1. single-timeport CR pending confirmation in ongoing patient with prior confirmed PR Analyses of DOR based on Findures 1 C-CR pending contenation / ingrang papers - you Kaplar-Meier estimates. suittmed C-PR, 8 ALK TKI-naive : chemotherapy 8 No prior chemotherapy Prior platinum chemotherapy Best % change in target lesions 20 0 20 $ 60 80 100 50 so PSI PR PM to PR BICK canded respendent rever, a reserve CNE person - your or, complete response DOR, - / - CASE a importer - PO - - FR - - No. - - - - - - ASCO - - PRESENTED ST. Jessica J. Lin, Mass General Brigham Cancer institute, Boston, MA, USA - - 2026 ASCO #ASCO26 - CONGUESS - ANNUAL MEETING Presentstion property . - - - Add - - - - - -

ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-nalve Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by 1 chemotherapy) 2 chemotherapy) $ chemotherapy) BICR N 253 N 63 N 190 Prior alectinib only + chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253) 46% (29/63) 26% (50/190)b [95% CI] [26, 37] [20, 33] >2 prior ALK TKIs 2 chemotherapy: [33, 59] ORR = 28% (56/198) CR, % (n/N) 2% (6/253) c 5% (3/63) d 2% (3/190) d Median duration of follow-up of 11.3 months " Includes 2 single-timepoint PR pending confirmation for ongoing patients. c Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. d Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-nalve + chemotherapy 60 HITIN: VI 100L 1 Prior ALK TKI (alectinib) 8 11965 1 Prior ALK TKI (other) 20 Best % change in target lesions 1171N G1202R 11171M UTHIR WITER G1202R G1J02R LYISSO VISAOL G12020 G12029 111715 01202R 01202R GT2029 SCOEND G1202R VISSOL 012029 2 Prior ALK TKIs 0 20 3 Prior ALK TKIs -40 . Prior platinum -60 chemotherapy 80 Secondary ALK mutations listed above the column 100 PR PO BICR blinded independent central review; CI, confidence Interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; so. stable disease; TKI, hyrosine kinase inhibitor 2026 ASCO PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN SOCIETY CLIPACAL OMCOLOGY ANNUAL MEETING Presentation N priparty of the author and ASCO Permission request for - contact KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Duration of Response Any prior Loriatinib- Loriatinib- TKI-Pretreated Kaplan-Meler Plot of DOR ALK TKI naive Advanced ALK+ experienced ALK TKI-Pretreated (1-5 prior ALK TKI (1-3 prior ALK TKI (1-5 prior ALK TKI NSCLC 1 chemotherapy) $ chemotherapy) 1 chemotherapy) 100 Kaplan-Meier Estimate N 77 N 29 N 48 89% 80% 75 DOR ≥ 6 months 76% 89% 68% (95% CI] [64, 84] [69, 96] [52, 80) Patients in Response (%) 60% 50 76% 68% 64% DOR ≥ 12 months 64% 80% 54% 54% 53% [95% CI] (51, 75) [58, 91] (38, 68] 47% 25 DOR > 18 months 53% 60% 47% [95% CI] [34, 68] [19, 85] [27, 64) 0 0 6 12 18 24 Months Median DOR [95% CI] NR [14.5, NE) NR [14.5, NEJ 17.6 (6.9, NE] At Risk Any prior 77 48 20 8 2 Loristinib. 0 Emerging median continues to mature. 29 21 7 naive 2 1 Prior alectinib only * chemotherapy: median DOR = NR (95% CI: NE, NE) Loriatinib 48 27 13 6 1 22 prior ALK TKIs $ chemotherapy: Emerging median DOR of 17.6 months (95% CI: 7.1. NE) experienced continues to mature. Cl, confidence Interval; DOR, duration of response; NE, not estimable; NR. not reached; TKI, tyrosine kinase Inhibitor. 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF #ASCO26 CUMICAL ONCOLGOR ANNUAL MEETING Presentation N property of the suthor and ASCO Permission required for reuse, contact permissions@esod.org KHOWLEDGE CONQUERS CANCER --- ALKOVE-1: Progression-Free Survival TKI-Pretreated Any prior Lorlatinib- Lorlatinib- Kaplan-Meler Plot of PFS ALK TKI naive Advanced ALK+ experienced ALK TKI-Pretreated (1-5 prior ALK TKI (1-3 prior ALK TKI (1-5 prior ALK TKI NSCLC 100 1 chemotherapy) $ chemotherapy) 1 chemotherapy) Kaplan-Meler Estimate N 253 N 63 N 190 76 PFS 2 6 months 50% 63% [95% CI] [43, 56] [49, 75] [38, 53] Event-free Probability (%) 63% 45% 53% 60 40% PFS ≥ 12 months 33% 53% 26% [95% CI] [26. 39] [38, 65] [19. 33] 25 50% 45% 33% 26% 26% 22% PFS 2 18 months 26% 40% 22% 0 [95% CI] [20, 34] [21, 58] [15. 30] 0 6 12 18 24 Months At Risk Any prior 263 103 44 10 2 Median PFS [95% CI] 5.7 [4.4. 6.5] 14.6 (4.8, NE] 4.6 [2.8, 6.2] Loriatioib- 83 34 10 3 1 naive Lorlatinib. 190 69 26 / f experienced : Emerging median continues to mature CI, confidence interval; NE, not estimable; PFS, progression-tree survival: TKI, tyrosine kinase inhibitor. 2026 ASCO PRESENTED or: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN VOCATY or CUINICAL ANNUAL MEETING Presentation . property of the wher and ASCO Parmission required for revers contact KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: CNS Activity TKI-Pretreated Any prior Loriatinib- Loriatinib- CNS Response- ALK TKI naive experienced Evaluable a Kaplan-Meier Plot of IC-DOR + chemotherapy + chemotherapy 1 chemotherapy RECIST 1.1, SICR TKI-Pretreated CNS Response-Evaluable N 92 N 24 N 68 [95% Ci] 100 92% 92% 92% IC-ORR, % (n/N) 32% (29/92) b 63% (15/24) 21% (14/68) 81% [22, 42] [41, 81] (12, 32] 75 71% 71% IC-CR, % (n/N) 13% (12/92) c 21% (5/24) 10% (7/68) Patients in Response (%) 71% 50 55% 55% *,* IC-DOR > 6 months d 81% [59, 91] 92% [57, 99] 71% [41, 88] IC-DOR ≥ 12 months d 71% [48, 85] 92% [57, 99] 55% [26, 77) 25 Emerging medians of (+) 21 6 months (95% Cl. 10.1, NE) and IC-DOR ≥ 18 months B 71% [48, 85] 92% [57, 99] 55% [26, 77) (+) months (95% Of: NE) continue to mature 0 Includes patients with measurable (≥5mm) CNS lesions by BICR at baseline and no brain radiation within 2 0 6 12 18 24 months before first dose of neladalkib. b Includes 2 single-timepoint IC-PR pending confirmation in ongoing Months AL Risk patients. Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior confirmed IC. PR. d Analyses of DOR based on Kaplan-Meier estimates Any prior 27 19 10 4 2 CNS response-evaluable after prior electinib only + chemotherapy: IC-ORR = 60% (9/15; 1 IC-uPR); Loriatinib- 13 0 4 naive 2 1 no intracranial progressors among confirmed intracranial responders. Lorlatinib. 14 CNS response-evaluable after 2 2 prior ALK TKIs 1 chemotherapy: IC-ORR = 25% (19/75; 1 IC-uPR); 10 6 2 experienced 1 IC-DOR at 6 months = 78% (95% Cl: 51, 91) and at 12 and 18 months = 60% (95% Cl: 39, 83). SICR, blinded Independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; DOR, duration of response; IC, Intracranial: NE, not estimable; NR, not reached; ORR, objective response rate; TKI, tyrosine Kinase Inhibitor; UPR, unconfirmed partial response. 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO MADRICAN #ASCO26 CURICAL ONCOLOGY ANNUAL MEETING Presentation 10 property of the nuther and ASCO Permission required for revise, correct permissiona@escom.org CNOWLEDGE CONGUERS CANCER

ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by + chemotherapy) + chemotherapy) + chemotherapy) BICR N 253 N 63 N = 190 Prior alectinib only + chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253)b 46% (29/63) 26% (50/190)ᵇ [95% CI] [26, 37] [20, 33] ≥2 prior ALK TKIs + chemotherapy: [33, 59] ORR = 28% (56/198) b CR, % (n/N) 2% (6/253) c 5% (3/63) d 2% (3/190) d Median duration of follow-up of 11.3 months. b Includes 2 single-timepoint PR pending confirmation for ongoing patients. C Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. d Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naïve ± chemotherapy 60 40 11171N: V1180L 1 Prior ALK TKI (alectinib) L119684 1 Prior ALK TKI (other) 20 Best % change in target lesions 11171N G1202R 11171N D1203N 11171N G1202R G1202R L1196Q V1180L G1202R G1202R 111715 G1202R G1202R G1202R G1202R G1202R V1150L G1202R 2 Prior ALK TKIs 0 -20 3 Prior ALK TKIs -40 + Prior platinum -60 chemotherapy 80 Secondary ALK mutations listed above the column -100 PD PD PD PD PD SD NE SD SD SD so SD so NE so SD so SD SD SD SD so SD SD SD PR SD PR PR PR PR PR so PR PR PR PR PR PR PR PR so PR PR PR PR VCR PR PR PR PR PR PR CR CR BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: CNS Activity TKI-Pretreated Any prior Lorlatinib- Lorlatinib- CNS Response- ALK TKI naive experienced Evaluable a Kaplan-Meier Plot of IC-DOR + chemotherapy ± chemotherapy ± chemotherapy RECIST 1.1, BICR TKI-Pretreated CNS Response-Evaluable N = 92 N 24 N = 68 [95% CI] 100 92% 92% 92% IC-ORR, % (n/N) 32% (29/92)b 63% (15/24) 21% (14/68) 81% [22, 42] [41, 81] [12, 32] 75 71% 71% IC-CR, % (n/N) 13% (12/92) c 21% (5/24) 10% (7/68) Patients in Response (%) 71% 50 55% 55% *, * IC-DOR ≥ 6 months d 81% [59, 91] 92% [57, 99] 71% [41, 88] IC-DOR 2 12 months d 71% [48, 85] 92% [57, 99] 55% [26, 77] 25 Emerging medians of (+) 21 6 months (95% Cl: 10.1. NE) and IC-DOR ≥ 18 months d 71% [48, 85] 92% [57, 99] 55% [26, 77] (+) 216 months (95% OI 21.6, NE) continue to mature 0 Includes patients with measurable (>5mm) CNS lesions by BICR at baseline and no brain radiation within 2 0 6 12 18 24 months before first dose of neladalkib. b Includes 2 single-timepoint IC-PR pending confirmation in ongoing Months At Risk patients. c Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior confirmed IC- PR. d Analyses of DOR based on Kaplan-Meier estimates. Any prior 27 19 10 4 2 CNS response-evaluable after prior alectinib only * chemotherapy: IC-ORR = 60% (9/15; 1 IC-uPR); Lorlatinib- 13 9 4 2 1 naive no intracranial progressors among confirmed intracranial responders. Lorlatinib- CNS response-evaluable after 2 2 prior ALK TKIs : chemotherapy: IC-ORR = 25% (19/75; 1 IC-uPR); 14 10 6 2 1 experienced IC-DOR at 6 months = 78% (95% Cl: 51, 91) and at 12 and 18 months = 66% (95% Cl: 39, 83). BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; DOR, duration of response; IC, intracranial; NE, not estimable; NR, not reached; ORR, objective response rate; TKI, tyrosine kinase inhibitor; uPR, unconfirmed partial response. 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Progression-Free Survival TKI-Pretreated Any prior Lorlatinib- Lorlatinib- Kaplan-Meier Plot of PFS ALK TKI naive Advanced ALK+ experienced ALK TKI-Pretreated NSCLC (1-5 prior ALK TKI (1-3 prior ALK TKI (1-5 prior ALK TKI 100 + chemotherapy) ± chemotherapy) + chemotherapy) Kaplan-Meier Estimate N 253 N 63 N 190 75 PFS ≥ 6 months 50% 63% [95% CI] [43, 56] [49, 75] [38, 53] Event-free Probability (%) 63% 45% 53% 50 40% PFS ≥ 12 months 33% 53% 26% [95% CI] [26, 39] [38, 65] [19, 33] 25 50% 45% 33% 26% 26% 22% PFS ≥ 18 months 26% 40% 22% 0 [95% CI] [20, 34] [21, 58] [15, 30] 0 6 12 18 24 Months At Risk Any prior 253 103 44 10 2 Median PFS [95% CI] 5.7 [4.4. 6.5] 14.5 [4.8, NE]ᵃ 4.6 [2.8, 6.2] Lorlatinib- 63 34 18 3 1 naive Loriatinib- 190 69 26 7 1 a Emerging median continues to mature. experienced CI, confidence interval; NE, not estimable; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: ALK G1202R Resistance Mutation Kaplan-Meier Plot of DOR TKI-Pretreated Any prior Lorlatinib- Lorlatinib- TKI-Pretreated with ALK G1202R Mutation with ALK G1202R ALK TKI naive experienced 100 mutation + chemotherapy a + chemotherapy ± chemotherapy 90% RECIST 1.1, BICR 77% 77% N 47 N 12 N 35 [95% CI] 75 84% 80% ORR, % (n/N) 68% (32/47)b 83% (10/12) 63% (22/35) b DOR ≥ 6 months c 90% [47, 99] 81% [56, 92] Patients in Response (%) 81% 81% 70% [53, 81] [52, 98] [45, 79] 50 67% 84% [65, 93] 25 DOR ≥ 12 months c 80% [61, 91] 77% [34, 94] 81% [56, 92] DOR ≥ 18 months c 70% [42, 86] 77% [34, 94] 67% [32, 87] 0 0 6 12 18 24 Patients may have had other mutations in addition to ALK G1202R. b Includes 1 single-timepoint PR Months pending confirmation for ongoing patient. c Analysis of DOR based on Kaplan-Meier estimates. At Risk ALK G1202R after prior alectinib only : chemotherapy: ORR = 82% (9/11); Any prior 31 23 13 7 2 DOR at 12 and 18 months = 74% (95% Cl: 29, 93). Lorlatinib- ALK G1202R after ≥2 prior ALK TKIs * chemotherapy: ORR = 64% (23/36, 1 uPR); 10 7 4 2 1 naive DOR at 12 months = 82% (95% Cl: 58, 93) and DOR at 18 months = 70% (95% Cl: 37, 88). Lorlatinib- 21 16 9 5 1 experienced Responses also observed in patients with: >2 ALK mutations after >2 prior ALK TKIs + chemotherapy: ORR = 58% ALK mutations other than G1202R, including C1156Y, I1171N, I1171T, (25*/43; includes 1 uPR), mDOR = NR (range, 2.2+ to 24.5+ months), F1174C, F1174L, V1180L, L1196M, L1198F, D1203N, E1210K, and G1269A DOR at 12 months = 69% (95% Cl: 45, 84) - Among the 25 patients with response, 9 had confirmed compound mutations (cis-allelic configuration). BICR, blinded independent central review; CI, confidence interval; DOR, duration of response; NE, not estimable; NR, not reached; ORR, objective response rate; TKI, tyrosine kinase inhibitor; uPR, unconfirmed partial response. 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY or CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

2026 ASCO® ANNUAL MEETING ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC Jessica J. Lin1, Enriqueta Felip², Byoung Chul Cho³, Benjamin Besse⁴, Geoffrey Liu⁵, Lorenza Landi⁶, Luis G. Paz-Ares⁷, Chiara Bennati⁸, Aurelie Swalduz9, Sanjay Popat¹⁰, Misako Nagasaka¹¹, Joshua E. Reuss¹², Christina S. Baik¹³, Julien Mazieres¹⁴, Melissa Johnson15, Adrianus Johannes de Langen¹⁶, Ji-Youn Han17, Malinda Itchins¹⁸, Viola W. Zhu¹⁹, Alexander Drilon20 Mass General Brigham Cancer Institute, Boston, MA, USA; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; 3Yonsei Cancer Center, Seoul, Republic of Korea; Paris Saclay University, Gustave Roussy, Villejuif, France; Princess Margaret Hospital, Toronto, Ontario, Canada; PIstituto Nazionale Tumori Regina Elena, IRCCS, Rome, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; SOspedale Santa Maria Delle Croci, Ravenna, Italy; Centre Léon Berard, Lyon, France; 10Lung Unit, Royal Marsden Hospital, London, United Kingdom; "University of California Irvine Medical Center, Orange, CA, USA; Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA; 13Fred Hutchinson Cancer Center, Seattle, WA, USA; "Centre Hospitalier de Toulouse, Toulouse, France; Sarah Cannon Research Institute Oncology Partners, Nashville, TN, USA; 16Department of Thoracic Oncology, Antoni van Leeuwenhoek hospital - Netherlands Cancer Institute, Amsterdam, The Netherlands; 17National Cancer Center, Goyang, Korea; ®Royal North Shore Hospital, Sydney, Australia; 19Nuvalent, Inc., Cambridge, MA, USA; 20Memorial Sloan Kettering Cancer Center and Weill Comell Medical Center, New York, NY, USA 2026 ASCO PRI SENTED IT: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN SOCIETY OF CLINICAL ONEDLOGY ANNUAL MEETING Presentation property of the author and ASCO Permission required for reuse, contact KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Pivotal TKI-Pretreated Patient Population Data cut-off: August 29, 2025 Total Enrolled: N = 781 Any ALK+ solid tumor, any dose Phase 1+ Phase 2 pooled Safety Population: N = 656 Advanced ALK+ NSCLC Received neladalkib at 150 mg QD Efficacy Population: Preliminary Data ALK TKI-Pretreated a TKI-Naive b with measurable disease by BICR with measurable disease by BICR Treated by September 30, 2024 Treated by (2 6 months DOR follow up) August 29, 2025 n = 253 n = 44 BICR, bilnded Independent central review; DOR, duration of response; NSCLC, non-small cell lung cancer; QD, once daily; TKI, tyrosine kinase inhibitor. a Includes 25 patients with other oncogenic driver(s) in addition to ALK: MET amplification (n = 9), KRAS G12C (n = 4*), MET mutation (n = 4), BRAF mutation (n = 4*), RET fusion (n - 2), ERBB2 mutation (n = 1), NTRK fusion (n = 1), FGFR3 fusion (n 0 1). [*One patient had both KRAS G12C and BRAF mutations.] b No patients with other oncogenic driver(s) in addition to ALK. 2026 ASCO #ASCO26 PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCETY OF ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org CLINICAL CHICOLOGY KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by * chemotherapy) + chemotherapy) * chemotherapy) BICR N 253 N 63 N 190 Prior alectinib only + chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253)b 46% (29/63) 26% (50/190)b [95% CI] [26, 37] [33, 59] >2 prior ALK TKIs + chemotherapy: [20, 33] ORR = 28% (56/198)b CR, % (n/N) 2% (6/253) c 5% (3/63) 2% (3/190) d a Median duration of follow-up of 11.3 months. b Includes 2 single-timepoint PR pending confirmation for ongoing patients. c Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. d Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naive + chemotherapy 50 11171N;V1100L 1 Prior ALK TKI (alectinib) 40 20 G1202R 196M (1171T;L1100M 11171N G1202R G1202R G1202R G1202R G1202R 1 Prior ALK TKI (other) Best % change in target lesions 11171N 11171N D1203N;411717 L1196Q V1100L G12028 111715 G1202R G1202R G1202R V1100L G1202N 1 2 Prior ALK TKIs 0 -20 3 Prior ALK TKIs 40 + Prior platinum 60 chemotherapy 80 Secondary ALK mutations listed above the column -100 PO PO as 2 an PO 10 90 PM 50 PR PR PH PR PR PR PR PR PA PR PR PR PR PR OR FR PR PR PR PR PR PR CR CR BICR, blinded Independent central review; CI, confidence Interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase Inhibitor. 2026 ASCO PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY or #ASCO26 CLINICAL OPICOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for геми, contact permissions@esco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: CNS Activity TKI-Pretreated Any prior Lorlatinib- Lorlatinib- CNS Response- ALK TKI naive experienced Evaluable a Kaplan-Meier Plot of IC-DOR + chemotherapy + chemotherapy + chemotherapy RECIST 1.1, BICR TKI-Pretreated CNS Response-Evaluable N 92 N 24 N 68 [95% CI] 100 92% 92% 92% IC-ORR, % (n/N) 32% (29/92) b 63% (15/24) 21% (14/68) 81% [22, 42] [41, 81] [12, 32] 75 71% 71% IC-CR, % (n/N) 13% (12/92) c 21% (5/24)c 10% (7/68) Patients in Response (%) 71% 50 55% 55% +,+ IC-DOR ≥ 6 months d 81% [59, 91] 92% (57, 99] 71% [41, 88] IC-DOR ≥ 12 months d 71% [48, 85] 92% [57, 99] 55% [26, 77] 25 Emerging modians of (+) 21 6 months (95% CL 10. 1, NE) and IC-DOR ≥ 18 months d 71% [48, 85] 92% [57, 99] 55% [26, 77] (+) 21;6 months (95% OI: 21.6, NE) continue to mature 0 Includes patients with measurable (25mm) CNS lesions by BICR at baseline and no brain radiation within 2 0 6 12 18 24 months before first dose of neladalkib. b Includes 2 single-timepoint IC-PR pending confirmation in ongoing Months At Risk patients. c Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior confirmed IC- PR. d Analyses of DOR based on Kaplan-Meier estimates. Any prior 27 19 10 4 2 CNS response-evaluable after prior alectinib only : chemotherapy: IC-ORR B 60% (9/15; 1 IC-uPR); Loriatinib- 13 9 naive 4 2 1 no intracranial progressors among confirmed intracranial responders. Lorlatinib- CNS response-evaluable after 2 2 prior ALK TKIs * chemotherapy: IC-ORR = 25% (19/75; 1 IC-uPR); 14 10 experienced 6 2 1 IC-DOR at 6 months = 78% (95% Cl: 51, 91) and at 12 and 18 months = 66% (95% Cl: 39, 83). BICR, blinded Independent central review; CI, confidence Interval; CNS, central nervous system; CR, complete response; DOR, duration of response; IC, Intracranial; NE, not estimable; NR, not reached; ORR, objective response rate; TKI, tyrosine kinase inhibitor; uPR, unconfirmed partial response. 2026 ASCO SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN SOCIETY or CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco. org. KNOWLEDGE CONQUERS CANCER

ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by + chemotherapy) + chemotherapy) + chemotherapy) BICR N 253 N 63 N 190 Prior alectinib only + chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253) 46% (29/63) 26% (50/190)ᵇ [95% CI] ≥2 prior ALK TKIs + chemotherapy: [26, 37] [33, 59] [20, 33] ORR = 28% (56/198) CR, % (n/N) 2% (6/253) c 5% (3/63) d 2% (3/190) d a Median duration of follow-up of 11.3 months. b Includes 2 single-timepoint PR pending confirmation for ongoing patients. c Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. d Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naive + chemotherapy 60 11171N: V1180L 1 Prior ALK TKI (alectinib) 40 20 11171N H171N .1 1 1 M171T;L1196M 1 D1203N; H1171T G1202R G1202R 1 Prior ALK TKI (other) Best % change in target lesions G1202R 11171N L1196Q V1180L G1202R G1202R 111715 G1202R G1202R G1202R G1202R G1202R V1180L G1202R 2 Prior ALK TKIs 0 -20 3 Prior ALK TKIs 40 + Prior platinum -60 chemotherapy -80 Secondary ALK mutations listed above the column 100 PD PD PD PD PD so NE SD so so so so SD NE so SD so so so so so so so so PR so PR PR PR PR so PR PR PR PR PR PR PR PR so PR PR PR PR PR VCR PR PR PR PR PR PR PR CR CR BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase Inhibitor. 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF #ASCO26 CURICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER ASCO ASCO ASCO ASCO ASCC --- ALKOVE-1: Duration of Response TKI-Pretreated Any prior Lorlatinib- Lorlatinib- Kaplan-Meler Plot of DOR Advanced ALK+ ALK TKI naive experienced ALK TKI-Pretreated NSCLC (1-5 prior ALK TKI (1-3 prior ALK TKI (1-5 prior ALK TKI * chemotherapy) * chemotherapy) * chemotherapy) Kaplan-Meier Estimate 100 N 77 N 29 N 48 89% 80% DOR ≥ 6 months 76% 89% 68% 75 (95% CI] (64, 84] [69, 96] (52, 80] Patients in Response (%) 60% 50 76% DOR ≥ 12 months 64% 80% 54% 68% 64% 54% 53% (95% CI] (51, 75] [58, 91] [38, 68] 47% 25 DOR > 18 months 53% 60% 47% [95% CI] [34, 68] (19, 85] [27, 64] 0 0 6 12 18 24 Months Median DOR [95% CI] NR (14.5, NE] NR [14.5, NE] 17.6 [6.9, NE]* At Risk Any prior 77 48 20 8 2 Emerging median continues to mature. Lorlatinib- 29 naive 21 7 2 1 Prior alectinib only * chemotherapy: median DOR - NR (95% CI: NE, NE). Lorlatinib- 48 27 >2 prior ALK TKIs : chemotherapy: Emerging median DOR of 17.6 months (95% CI: 7.1, NE) experienced 13 6 1 continues to mature. CI, confidence interval; DOR, duration of response; NE, not estimable; NR, not reached; TKI, tyrosine kinase inhibitor. 2026 ASCO PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN SOCIETY OF CURRICAL ANNUAL MEETING Presentation is property of the author and ASCO Permission required for - contact permissions@asco.org KNOWLEDGE CONQUERS CANCER ASCO ASCO ASCO ASCO ASCO --- ALKOVE-1: CNS Activity TKI-Pretreated Any prior Lorlatinib- Lorlatinib- CNS Response- ALK TKI naive experienced Evaluable a Kaplan-Meier Plot of IC-DOR + chemotherapy + chemotherapy + chemotherapy RECIST 1.1, BICR TKI-Pretreated CNS Response-Evaluable N 92 N 24 N 68 [95% CI] 100 92% 92% 92% IC-ORR, % (n/N) 32% (29/92) b 63% (15/24)b 21% (14/68) 81% [22, 42] [41, 81] [12, 32] 75 71% 71% IC-CR, % (n/N) 13% (12/92) c 21% (5/24) c 10% (7/68) Patients in Response (%) 71% 50 55% 55% #,* IC-DOR ≥ 6 months d 81% [59, 91] 92% [57, 99] 71% [41, 88] IC-DOR ≥ 12 months d 71% [48, 85] 92% [57, 99] 55% [26, 77] 25 Emerging medians of (+) 21 6 months (95% CI: 10. NE) and IC-DOR ≥ 18 months d 71% [48, 85] 92% [57, 99] 55% [26, 77] (+) 21j6 months (95% Of: 21.6, NE) continue to mature 0 a Includes patients with measurable (>5mm) CNS lesions by BICR at baseline and no brain radiation within 2 0 6 12 18 24 months before first dose of neladalkib. b Includes 2 single-timepoint IC-PR pending confirmation in ongoing Months At Risk patients. Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior confirmed IC- PR. d Analyses of DOR based on Kaplan-Meier estimates. Any prior 27 19 10 4 2 CNS response-evaluable after prior alectinib only + chemotherapy: IC-ORR = 60% (9/15; 1 IC-uPR); Lorlatinib- 13 naive 9 4 2 1 no intracranial progressors among confirmed intracranial responders. Lorlatinib- CNS response-evaluable after ≥2 prior ALK TKIs * chemotherapy: IC-ORR = 25% (19/75; 1 IC-uPR); 14 10 experienced 6 2 1 IC-DOR at 6 months = 78% (95% Cl: 51, 91) and at 12 and 18 months = 66% (95% CI: 39, 83). BICR, blinded independent central review; CI, confidence Interval; CNS, central nervous system; CR, complete response; DOR, duration of response; IC, Intracranial; NE, not estimable; NR, not reached; ORR, objective response rate; TKI, tyrosine kinase inhibitor; uPR, unconfirmed partial response. 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF #ASCO26 CUNICAL ORCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Safety in Advanced ALK+ NSCLC Dose reduction due to TEAE: 17% All Treatment-Emergent Adverse Events (TEAEs) in ≥ 15% Most common (≥1% of patients): of TKI-Naïve or TKI-Pretreated Patients with Advanced ALT increased (10%), AST increased (8%) a ALK+ NSCLC Receiving Neladalkib 150 mg QD (N = 656) Discontinuation due to TEAE: 5% Preferred Term Any Grade Grade ≥3 Most common (≥1% of patients): ALT increased (2%), AST increased (1%) ALT increased 47% 20% Most common TEAE were transaminase elevations AST increased 44% 16% Most were asymptomatic lab abnormalities, and observed to be low- Constipation 28% 0.2% grade, transient, and reversible with dose interruptions or reductions Preliminary data suggest increased incidence in less heavily Dysgeusia 23% 0 pre-treated patients Peripheral edema 18% 0.3% Enhanced monitoring and prompt dose interventions implemented in the protocol for the Phase 3 ALKAZAR trial Cough 16% 0.5% Nausea Overall safety profile consistent with avoiding TRK-related 16% 0.8% neurotoxicities Data pooled for patients in the Phase 1 or Phase 2 portion of ALKOVE-1 with a data cut-off of August 29, 2025. Patients received at least 1 dose of neladalkib at RP2D of 150 mg QD with median duration of exposure of 6.0 months (range: 0.1, 28.4). ALT, alanine aminotransferase; AST, aspartate aminotransferase; NSCLC, non-small cell lung cancer; RP2D, recommended phase 2 dose; QD, once-daily; TEAE, treatment emergent adverse event; TKI, tyrosine kinase inhibitor. a Not mutually exclusive: Dose reduction due to any transaminase elevation observed in 11% of patients. 2026 ASCO PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF #ASCO26 CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

ALKOVE-1 Preliminary Data: TKI-Naïve Patients with Advanced ALK+ NSCLC ALK TKI-naive, BICR Response-evaluable CNS Response-evaluable ALK TKI-naïve, BICR N = 44 N=9 ORR, % (n/N) 86% (38/44)ᵃ IC-ORR, % (n/N) 78% (7/9) CR, % (n/N) 9% (4/44) b IC-CR, % (n/N) 44% (4/9) % DOR ≥ 12 months [95% CI] 91% [70, 98] IC-DOR No CNS progression events among intracranial responders DOR range 1.7+ to 14.8+ months IC-DOR range 3.1+ to 7.0+ months a Includes 2 single-timepoint PR pending confirmation for ongoing patients. b Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Analyses of DOR based on d Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior Kaplan-Meier estimates. confirmed IC-PR. 60 ALK TKI-naïve ± chemotherapy 40 No prior chemotherapy Prior platinum chemotherapy Best % change in target lesions 20 0 -20 -40 -60 -80 -100 SD SD uPR uPR SD PR PR PR SD PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR SD PR PR PR PR PR CRCR CR CR BICR blinded independent central review, CI, confidence interval CNS central nervous system CR. complete response, DOR duration of response ORR objective response rate PD progressive disease PR. partial response SD stable disease TKI. tyrosine kinase inhibitor 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CUNICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Safety in Advanced ALK+ NSCLC Dose reduction due to TEAE: 17% All Treatment-Emergent Adverse Events (TEAEs) in > 15% Most common (≥1% of patients): of TKI-Naïve or TKI-Pretreated Patients with Advanced ALT increased (10%), AST increased (8%) a ALK+ NSCLC Receiving Neladalkib 150 mg QD (N = 656) Discontinuation due to TEAE: 5% Preferred Term Any Grade Grade ≥3 Most common (≥1% of patients): ALT increased (2%), AST increased (1%) ALT increased 47% 20% Most common TEAE were transaminase elevations AST increased 44% 16% Most were asymptomatic lab abnormalities, and observed to be low- Constipation 28% 0.2% grade, transient, and reversible with dose interruptions or reductions Preliminary data suggest increased incidence in less heavily Dysgeusia 23% 0 pre-treated patients Peripheral edema 18% 0.3% Enhanced monitoring and prompt dose interventions implemented in the protocol for the Phase 3 ALKAZAR trial Cough 16% 0.5% Overall safety profile consistent with avoiding TRK-related Nausea 16% 0.8% neurotoxicities Data pooled for patients in the Phase 1 or Phase 2 portion of ALKOVE-1 with a data cut-off of August 29, 2025. Patients received at least 1 dose of neladalkib at RP2D of 150 mg QD with median duration of exposure of 6.0 months (range: 0.1, 28.4). ALT, alanine aminotransferase; AST, aspartate aminotransferase; NSCLC, non-small cell lung cancer; RP2D, recommended phase 2 dose; QD, once-daily; TEAE, treatment emergent adverse event; TKI, tyrosine kinase inhibitor. a Not mutually exclusive: Dose reduction due to any transaminase elevation observed in 11% of patients. 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Summary In these data from the ALKOVE-1 study of TKI-pretreated patients with advanced ALK+ NSCLC, neladalkib demonstrated a clinical profile consistent with its design goals: Meaningful clinical responses for TKI-pretreated patients (range 1-5 prior ALK TKI) across both lorlatinib-naive (ORR = 46%; median DOR not reached, DOR ≥12 months for 80%) and lorlatinib-experienced patients (ORR = 26%; median DOR of 17.6 months) Intracranial activity, including in patients who previously received lorlatinib, a population where no other TKI has shown activity (lorlatinib-naïve: IC-ORR = 63%; DOR ≥12 months for 92%; lorlatinib-experienced: IC-ORR = 21%; DOR ≥12 months for 55%) Activity in patients with ALK G1202R single or compound resistance mutations (lorlatinib-naïve: ORR = 83%, DOR ≥12 months for 77%; lorlatinib-experienced: ORR = 63%; DOR ≥12 months for 81%) Generally well-tolerated with low rates of dose reduction (17%) and treatment discontinuation (5%) due to TEAEs, consistent with its ALK-selective, TRK-sparing design Encouraging efficacy and safety data support investigation in the front-line setting in the ongoing phase 3 ALKAZAR trial (NCT06765109) 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF #ASCO26 CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

2026ASCO ANNUAL MEETING ASCC ASCC --- 2026 ASCO ANNUAL MEETING ALKOVE-1: Efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC Jessica J. Lin1, Enriqueta Felip², Byoung Chul Cho³, Benjamin Besse⁴, Geoffrey Liu⁵, Lorenza Landi⁶, Luis G. Paz-Ares⁷, Chiara Bennati⁸, Aurelie Swalduz⁹, Sanjay Popat¹⁰, Misako Nagasaka¹¹, Joshua E. Reuss¹², Christina S. Baik¹³, Julien Mazieres¹⁴, Melissa Johnson¹⁵, Adrianus Johannes de Langen¹⁶, Ji-Youn Han¹⁷, Malinda Itchins¹⁸, Viola W. Zhu¹⁹, Alexander Drilon20 Mass General Brigham Cancer Institute, Boston, MA, USA; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; 3Yonsei Cancer Center, Seoul, Republic of Korea; Paris Saclay University, Gustave Roussy, Villejuif, France; Princess Margaret Hospital, Toronto, Ontario, Canada; 61stituto Nazionale Tumori Regina Elena, IRCCS, Rome, Italy; Hospital Universitario 12 de Octubre, Madrid, Spain; Ospedale Santa Maria Delle Croci, Ravenna, Italy; Centre Leon Bérard, Lyon, France; 10Lung Unit, Royal Marsden Hospital, London, United Kingdom; "University of California Irvine Medical Center, Orange, CA, USA; 12Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA; 13Fred Hutchinson Cancer Center, Seattle, WA, USA; 14Centre Hospitalier de Toulouse, Toulouse, France; Sarah Cannon Research Institute Oncology Partners, Nashville, TN, USA; 16Department of Thoracic Oncology, Antoni van Leeuwenhoek hospital Netherlands Cancer Institute, Amsterdam, The Netherlands; 17National Cancer Center, Goyang, Korea; 18Royal North Shore Hospital, Sydney, Australia; Nuvalent, Inc., Cambridge, MA, USA; 20Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY, USA 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: A Global First-in-Human Phase 1/2 Clinical Trial of Neladalkib in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626) PHASE 1 PHASE 2: Neladalkib 150 mg QD (RP2D) PATIENT PRIOR LINES PRIOR ALK TKI PHASE 2 ENDPOINTS POPULATION CHEMO/I-O 1 prior 2G (ceritinib, alectinib, or brigatinib) 0-2 Neladalkib dose escalation 2-3 prior, any generation 0-2 (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib a) (15 200 mg Primary: ORR by BICR ALK+ NSCLC QD) in patients 1 prior 3G (lorlatinib) ≤1 Secondary: Additional efficacy measures (DOR, with advanced None (TKl-naïve) â 1 TTR, PFS, OS), ALK+ solid intracranial activity, overall safety and tolerability, tumors Any (not eligible for other cohorts) Any confirmation of PK profile Other ALK+ ≥ 1 prior ALK TKI or systemic therapy Solid Tumors Any (or for whom no satisfactory standard therapy exists) Neladalkib is an investigational product and has not been approved by the FDA or any other health authority. BICR, blinded independent central review; chemo, chemotherapy; DOR, duration of response; G, generation; I-O, immunotherapy; NSCLC non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetic; QD, once daily; RP2D, recommended phase 2 dose; TKI, tyrosine kinase inhibitor; TRK, tropomyosin-related kinase; TTR, time to response. a Excludes patients who received lortatinib as the 1st prior ALK TKI. 2026 ASCO #ASCO26 PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Patient Population ALK TKI-Pretreated a ALK TKI-Pretreated a Patient Characteristic Efficacy Population Treatment History Efficacy Population N = 253 N = 253 Age, median (range) 56 (24 83) Prior anticancer therapy, median (range) 3 (1- 11) Female 145 (57%) Chemotherapy 128 (51%) No history of smoking 167 (66%) Prior ALK TKIs 1 Geographic region 1G crizotinib 67 (26%) Asia Pacific 50 (20%) 2G any 2G 240 (95%) Europe 101 (40%) alectinib 220 (87%) North America 102 (40%) brigatinib 55 (22%) ECOG PS ceritinib 27 (11%) 0 90 (36%) ensartinib 3 (1%) 1 163 (64%) 3G lorlatinib 190 (75%) Baseline CNS metastases b 101 (40%) Lorlatinib-naive g.h 63 (25%) Secondary ALK mutation c 91 (36%) ≥1 prior 2G 63/63 (100%) G1202R mutation d 47 (19%) 1 ALK TKI (alectinib) 44/63 (70%) ≥2 ALK mutations e 43 (17%) ⥠2 ALK TKIs 17/63 (27%) CNS, central nervous system; G, generation; PS, performance score; TKI, tyrosine kinase inhibitor. Lorlatinib-experienced 190 (75%) a Includes 25 patients with other oncogenic driver(s) in addition to ALK. Includes patients with treated or untreated, measurable or non-measurable CNS lesions by BICR. C ALK mutations as per ≥2 ALK TKIs, including 2G and lorlatinib 177/190 (93%) local or central testing of blood (ctDNA) or tissue. d Patients may have had other mutations in addition to ALK G1202R. e Includes 15 patients with confirmed compound mutations (cis-allelic configuration). ≥3 ALK TKIs, including 2G and lorlatinib 69/190 (36%) I One patient received an investigational TKI. 0 No patients received crizotinib as the only prior ALK TKI. 46 patients received 1 prior ALK TKI only (alectinib, n = 44; brigatinib, n = 2). 2026 ASCO #ASCO26 PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

ALKOVE-1: A Global First-in-Human Phase 1/2 Clinical Trial of Neladalkib in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626) PHASE 1 PHASE 2: Neladalkib 150 mg QD (RP2D) PATIENT PRIOR LINES PRIOR ALK TKI PHASE 2 ENDPOINTS POPULATION CHEMO/I-O 1 prior 2G (ceritinib, alectinib, or brigatinib) 0-2 Neladalkib dose escalation 2-3 prior, any generation 0-2 (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib ") (15- 200 mg Primary: ORR by BICR ALK+ NSCLC QD) in patients 1 prior 3G (lorlatinib) ≤1 Secondary: Additional efficacy measures (DOR, with advanced None (TKI-naive) 51 TTR, PFS, OS), ALK+ solid intracranial activity, overall tumors Any (not eligible for other cohorts) safety and tolerability, Any confirmation of PK profile Other ALK+ ⥠prior ALK TKI or systemic therapy Solid Tumors Any (or for whom no satisfactory standard therapy exists) Neladalkib is an investigational product and has not been approved by the FDA or any other health authority. BICR, blinded independent central review; chemo, chemotherapy; DOR, duration of response; G, generation; I-O, immunotherapy; NSCLC, non-small cell lung cancer; ORR, objective response rate; os, overall survival; PFS, progression-free survival; PK, pharmacokinetic; QD, once daily; RP2D, recommended phase 2 dose; TKI, tyrosine kinase inhibitor; TRK, tropomyosin-related kinase; TTR, time to response. a Excludes patients who received lorlatinib as the 1st prior ALK TKI. 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN SOCIETY OF CUPICAL ONCOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Patient Population ALK TKI-Pretreated ALK TKI-Pretreated a Patient Characteristic Efficacy Population Treatment History Efficacy Population N = 253 N = 253 Age, median (range) 56 (24 83) Prior anticancer therapy, median (range) 3 (1- 11) Female 145 (57%) Chemotherapy 128 (51%) No history of smoking 167 (66%) Prior ALK TKIs I Geographic region 1G crizotinib 67 (26%) Asia Pacific 50 (20%) 2G any 2G 240 (95%) Europe 101 (40%) alectinib 220 (87%) North America 102 (40%) brigatinib 55 (22%) ECOG PS ceritinib 27 (11%) 0 90 (36%) ensartinib 3 (1%) 1 163 (64%) 3G lorlatinib 190 (75%) Baseline CNS metastases b 101 (40%) Lorlatinib-naive g.h 63 (25%) Secondary ALK mutation c 91 (36%) ¥1 prior 2G 63/63 (100%) G1202R mutation d 47 (19%) 1 ALK TKI (alectinib) 44/63 (70%) >2 ALK mutations e 43 (17%) ≥ 2 ALK TKIs 17/63 (27%) CNS, central nervous system; G, generation; PS, performance score; TKI, tyrosine kinase inhibitor. Lorlatinib-experienced 190 (75%) a Includes 25 patients with other oncogenic driver(s) In addition to ALK. Includes patients with treated or untreated, measurable or non-measurable CNS lesions by BICR. ALK mutations as per >2 ALK TKIs, including 2G and lorlatinib 177/190 (93%) local or central testing of blood (ctDNA) or tissue. d Patients may have had other mutations in addition to ALK G1202R. Includes 15 patients with confirmed compound mutations (cis-allelic configuration). ≥3 ALK TKIs, including 2G and lorlatinib 69/190 (36%) I One patient received an Investigational TKI. 0 No patients received crizotinib as the only prior ALK TKI. 46 patients received 1 prior ALK TKI only (alectinib, n = 44; brigatinib, n = 2). 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO AMERICAN SOCIETY OF CUPICAL CHOOLOGY ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive Lorlatinib-experienced NSCLC (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by + chemotherapy) + chemotherapy) + chemotherapy) BICR N 253 N 63 N 190 Prior alectinib only + chemotherapy: ORR = 48% (21/44, 5% CR) ORR, % (n/N) 31% (79/253)b 46% (29/63) 26% (50/190)b [95% CI] [26, 37] [33, 59] [20, 33] ≥2 prior ALK TKIs ± chemotherapy: ORR = 28% (56/198)ᵇ CR, % (n/N) 2% (6/253) C 5% (3/63) ᵈ 2% (3/190) Median duration of follow-up of 11.3 months. b Includes 2 single-timepoint PR pending confirmation for ongoing patients. c Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. d Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naïve ± chemotherapy 60 11171N; : V1180L 1 Prior ALK TKI (alectinib) 40 20 H171T: L1196M M171T;L1196M D1203N; 111717 1 Prior ALK TKI (other) Best % change in target lesions 11171N G1202R 11171N 11171N G1202R G1202R L1196Q V1100L G1202R G1202R 111715 G1202R G1202R BEOCIO G1202R G1202R V1180L G1202R 2 Prior ALK TKIs 0 -20 3 Prior ALK TKIs -40 + Prior platinum -60 chemotherapy -80 Secondary ALK mutations listed above the column -100 PD PD PD SD SD so so SD SD SD so so SD SD so PM so PR PR PR PR PR PR PR OR PR PR PR CR BICR, blinded independent central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN SOCIETY or #ASCO26 CUNICAL CHCOLOGE ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org KNOWLEDGE CONQUERS CANCER --- ALKOVE-1 Preliminary Data: TKI-Naïve Patients with Advanced ALK+ NSCLC ALK TKI-naïve, BICR Response-evaluable ALK TKI-naïve, BICR CNS Response-evaluable N 44 N=9 ORR, % (n/N) 86% (38/44)ᵃ IC-ORR, % (n/N) 78% (7/9) CR, % (n/N) 9% (4/44) b IC-CR, % (n/N) 44% (4/9) % DOR ≥ 12 months [95% CI] c 91% [70, 98] IC-DOR No CNS progression events among intracranial responders DOR range 1.7+ to 14.8+ months IC-DOR range 3.1+ to 7.0+ months a Includes 2 single-timepoint PR pending confirmation for ongoing patients. b Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Analyses of DOR based on d Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior Kaplan-Meier estimates. confirmed IC-PR. 60 ALK TKI-naïve ± chemotherapy 40 No prior chemotherapy Prior platinum chemotherapy Best % change in target lesions 20 0 -20 -40 -60 -80 -100 SD SD uPR uPR SD PR PR PR SD PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR PR SD PR PR PR PR PR CRCR CR CR BICR, blinded independent central review, CI, confidence interval; CNS, central nervous system; CR, complete response; DOR, duration of response; ORR, objective response rate; PD, progressive disease; PR, partial response, so, stable disease, TKI, tyrosine knase inhibitor 2026 ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN #ASCO26 CURRCAL ONE ANNUAL MEETING Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org KNOWLEDGE CONQUERS ID

ALKOVE-1: A Global First-in-Human Phase 1/2 Clinical Trial of Neladalkib in Advanced ALK-Positive NSCLC and Other Solid Tumors (NCT05384626) 202 ANN PHASE 1 PHASE 2: Neladalkib 150 mg QD (RP2D) PATIENT POPULATION PRIOR ALK TKI PRIOR LINES CHEMO/I-O PHASE 2 ENDPOINTS Neladalkib dose 1 prior 2G (ceritinib, alectinib, or brigatinib) 0-2 escalation 2-3 prior, any generation (15 200 mg (crizotinib, ceritinib, alectinib, brigatinib, or lorlatinib ) 0-2 Primary: ORR by BICR QD) in patients ALK+ NSCLC 1 prior 3G (lorlatinib) $1 Secondary: Additional with advanced efficacy measures (DOR, ALK+ solid None (TKI-naïve) ≤1 TTR, PFS, OS), intracranial activity, overall tumors Any (not eligible for other cohorts) Any safety and tolerability, confirmation of PK profile Other ALK+ ≥1 prior ALK TKI or systemic therapy Solid Tumors (or for whom no satisfactory standard therapy exists) Any Neladalkib is an investigational product and has not been approved by the FDA or any other health authority. BICR, blinded independent central review; chemo, chemotherapy; DOR, duration of response; G, generation; I-O, immunotherapy; NSCLC, non-small cell lung cancer, ORR, objective response rate, OS, overall survival; PFS, progression-free survival; PK, pharmacokinetic; QD, once daily; RP2D, recommended phase 2 dose; TKI, tyrosine kinase inhibitor; TRK, tropomyosin-related kinase; TTR, time to response. Excludes patients who received lorlatinib as the 1st prior ALK TKI. ASCO PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ASCO AMERICAN #ASCO26 CONCAL SHOULDER MEETING Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER 2026ASCO --- ALKOVE-1: Objective Response in ALK TKI-Pretreated Patients Advanced ALK+ Any prior ALK TKI a Lorlatinib-naive NSCLC Lorlatinib-experienced (1-5 prior ALK TKIs (1-3 prior ALK TKIs (1-5 prior ALK TKIs RECIST v1.1 by + chemotherapy) + chemotherapy) : chemotherapy) BICR N 253 N 63 N 190 Prior alectinib only : chemotherapy: ORR, % (n/N) 31% (79/253) ORR = 48% (21/44, 5% CR) 46% (29/63) 26% (50/190)b [95% CI] [26, 37] [33, 59] [20, 33] ≥2 prior ALK TKIs : chemotherapy: ORR = 28% (56/198) CR, % (n/N) 2% (6/253) 5% (3/63) 2% (3/190) d Median duration of follow-up of 11.3 months. b Includes 2 single-timepoint PR pending confirmation for ongoing patients. Includes 2 single-timepoint CR pending confirmation in ongoing patients with prior confirmed PR. 6 Includes 1 single-timepoint CR pending confirmation in ongoing patient with prior confirmed PR. Lorlatinib-naïve + chemotherapy 60 1 Prior ALK TKI (alectinib) 40 . 11171N; 180L 20 G1202R 11171N : 1 196M H171T;L1196M 1 Prior ALK TKI (other) INCOCIO 11171N G1202N Desire VISIOL TOOL 11171N GT G1202R G1 G1202R H1718 01202K G1 202R NEDEVO NEGELD MEDELO VI180L G1202N 2 Prior ALK TKIs Best % change in target lesions 0 3 Prior ALK TKIs 20 + Prior platinum 40 chemotherapy 60 Secondary ALK mutations listed above the column -80 -100 SD BICR, blinded PD independent PD PO central review; CI, confidence interval; CR, complete response; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease; TKI, tyrosine kinase inhibitor. ASCO WERCAN COMER PRE SENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA ENQWLEDGE CONQUERS CANCER ASCO #ASCO26 Presentation is property of the author and ASCO. Permission required for reuse, contact permissions@asco.org L MEETING 2026ASCO ANNUAL MEETING ASCO ASCO ASCO --- ALKOVE-1: Progression-Free Survival TKI-Pretreated Any prior Lorlatinib- Loriatinib- Kaplan-Meier Plot of PFS Advanced ALK+ ALK TKI naive experienced ALK TKI-Pretreated (1-5 prior ALK TKI (1-3 prior ALK TKI (1-5 prior ALK TKI NSCLC 100 + chemotherapy) + chemotherapy) * chemotherapy) Kaplan-Meier Estimate N 253 N 63 N 190 75 PFS ≥ 6 months 50% 63% [95% CI] [43,56] [49, 75] [38,53] Event-free Probability (%) 63% 45% 53% 50 40% PFS ≥ 12 months 33% 53% 26% 25 50% [26, 39] [38,65] [19,33] [95% CI] 45% 33% 26% 26% 22% 22% 0 PFS ≥ 18 months 26% 40% [15,30] 0 6 12 18 24 [95% CI] [20, 34] [21,58] Months Ad Risk Any prior 253 103 44 10 2 Median PFS [95% CI] 5.7 [4.4. 6.5] 14.5 [4.8, NE] 4.6 [2.8, 6.2] Lorlatinib- 63 34 18 3 1 naive Lorlatinib 190 09 28 / 1 experienced Emerging median continues to mature. CI. confidence interval; NE, not estimable; PFS, progression-free survival; TKI, tyrosine kinase inhibitor. ASCO CUMICAL PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA KNOWLEDGE CONQUERS CANCER ASCO #ASCO26 Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco MEETING 2026ASCO ANNUAL MEETING ASCO ASCO ASCO --- ALKOVE-1: CNS Activity TKI-Pretreated CNS Response- Any prior Lorlatinib- Lorlatinib- Evaluable ALK TKI naive experienced RECIST 1.1, BICR ± chemotherapy + chemotherapy 1 chemotherapy Kaplan-Meier Plot of IC-DOR [95% CI] N 92 N 24 N 68 TKI-Pretreated CNS Response-Evaluable 100 32% (29/92) 63% (15/24)b 92% 92% IC-ORR, % (n/N) 21% (14/68) 92% [22,42] [41,81] [12,32] 81% 75 71% 71% IC-CR, % (n/N) 13% (12/92) 21% (5/24) 10% (7/68) Patients in Response (%) 71% IC-DOR ≥ 6 months d 81% [59, 91] 50 92% [57,99] 71%[41,88] 55% 55% 1,4 IC-DOR 2 12 months d 71% [48, 85] 92% [57,99] 55% [26, 77] 25 IC-DOR ≥ 18 months d 71% [48, 85] 92% [57,99] 55% [26, 77] Emerging medians of (1) 21 5 months (35% a 10 NE) and (4) 21:6 months (95% 0 21.6, NE) continue to mature 0 I Includes patients with measurable (>5mm) CNS lesions by BICR at baseline and no brain radiation within 2 0 6 12 18 24 months before first dose of neladalkib. b Includes 2 single-timepoint IC-PR pending confirmation in ongoing Months patients. Includes 1 single-timepoint IC-CR pending confirmation in ongoing patient with prior confirmed IC- AL Risk PR. d Analyses of DOR based on Kaplan-Meier estimates. Any prior 27 19 10 4 2 CNS response-evaluable after prior alectinib only 1 chemotherapy: IC-ORR : 60% (9/15; 1 IC-uPR); Lorlatinib- 13 naive 9 4 2 1 no intracranial progressors among confirmed intracranial responders. Lorlatinib- CNS response-evaluable after ≥2 prior ALK TKIs : chemotherapy: IC-ORR = 25% (19/75; 1 C-uPR); 14 experienced 10 $ 2 1 IC-DOR at 6 months = 78% (95% Cl: 51, 91) and at 12 and 18 months = 66% (95% Cl: 39, 83). BICR, blinded independent central review; CI, confidence interval; CNS, central nervous system; CR, complete response; DOR, duration of response; IC, intracranial; NE, not estimable, NR, not reached; ORR, objective response rate; TKI, tyrosine kinase inhibitor; uPR, unconfirmed partial response. ASCO PRESENTED BY: Jessica J. Lin, Mass General Brigham Cancer Institute, Boston, MA, USA #ASCO26 ASCO ONCE - MEETING Presentation is property of the author and ASCO Permission required for revse, contact permissions@asco.org KNOWLEDGE CONQUERS CANCER

ASCO 2026 ALKOVE-1 The Next ALK Frontier MV ONCO ONE CORE TAKEAWAY ALK+ NSCLC Sequential ALK TKIs transformed survival Lorlatinib resistance eventually emerges CNS progression compound mutations limited targeted options " The key clinical question: "Can targeted therapy continue beyond lorlatinib?" " Neladalkib Designed for modern resistance biology G1202R activity brain penetrance TRK-sparing design G1202R ORR Post-lorlatinib ORR 68% CNS activity 26% preserved Heavily pretreated population 91% prior lorlatinib Post-lorlatinib ALK inhibition may still be biologically actionable. Resistance biology may remain targetable. Jessica J. Lin et al ASCO 2026

1 ALKOVE-1 Neladalkib in Advanced ALK+ NSCLC Meaningful post-lorlatinib activity with strong G1202R and CNS efficacy signals. MV Onco 2 WHY THIS STUDY MATTERS Can targeted therapy continue ALK+ Sequential Lorlatinib CNS progression + Few targeted NSCLC ALK TKIs resistance compound mutations options beyond improve survival eventually become major remain lorlatinib? emerges challenges 3 DESIGNED FOR MODERN 4 HEAVILY PRETREATED POPULATION ALK RESISTANCE BIOLOGY Heavily post-lorlatinib population Targets ALK single + compound mutations 253 3 78% Brain-penetrant Efficacy-evaluable Median prior Received >2 Active in G1202R patients therapies ALK TKIs resistance ALK TRK-sparing design 91% 40% 19% TRK Prior CNS G1202R lorlatinib disease mutations 5 MAJOR EFFICACY SIGNAL All TKI-pretreated Prior lorlatinib G1202R mutation ORR ORR ORR Responses remained 31% 26% 68% durable despite extensive prior ALK exposure. 6 CNS ACTIVITY REMAINED DURABILITY EARLY FRONTLINE SIGNAL CLINICALLY MEANINGFUL IC-ORR Post- lorlatinib mDOR: 32% 63% overall in lorlatinib- 17.6 ORR IC-ORR naive pts months Brain penetrance remains 86% 78% a defining strength. Durability may matter Preliminary but No CNS progression events more than raw ORR. observed in early no naive cohort highly encouraging. 7 LIMITATIONS CLINICAL INTERPRETATION Single-arm study Neladalkib may extend Early dataset the future ALK sequencing No comparative efficacy yet ! pathway beyond lorlatinib. Small molecular subgroups 9 Post-lorlatinib ALK inhibition may still be biologically actionable. Neladalkib demonstrated meaningful activity in resistant ALK+ NSCLC - especially in G1202R mutations and CNS disease. Jessica J. Lin et al ASCO 2026

Efficacy Parameter All ALK TKI Pre- ALK TKI Pre- treated treated, (RECIST v1.1, BICR) + chemo Lorlatinib-naive ± chemo ORR % (n/N) 31 (79/253) b 46 (29/63)ᶜ 95% CI 26, 37 33, 59 % DOR ≥ 12 m (95% CI) / 18 m 64 (51, 75) / 53 (34, 80 (58, 91) / 60 (19, (95% CI) d 68) 85) G1202R Mutation ORR % (n/N) 68 (32/47)e,f 83 (10/12) 95% CI 53, 81 52, 98 % DOR ≥ 12 md (95% CI) 80 (61, 91) 77 (34, 94) Intracranial Activity IC-ORR % (n/N) 32 (29/92)9, h 63 (15/24)9 95% CI 22, 42 41, 81 % IC-DOR ≥ 12 m d (95% CI) 71 (48, 85) 92 (57, 99)

: I I e - - PRECISELY Surget - Targeted Therapies - Physician for patients with cancer - Compete - THE MINALENT APPROACH I | J.P.Morgan J.P.Morgan